March 29, 2022

Eisai: Announcement About an Approval for Additional Indication of Jyseleca, JAK inhibitor

TOKYO, Mar 28, 2022 – (JCN Newswire via SEAPRWire.com) – Gilead Sciences K.K., Eisai Co., Ltd. and EA Pharma Co., Ltd. announced that Gilead acquired…

April 23, 2021

Eisai: Gilead Sciences Submits New Drug Application in Japan for Filgotinib for the Treatment of Ulcerative Colitis with an Inadequate Response to Conventional Therapies

TOKYO, Apr 23, 2021 – (JCN Newswire via SEAPRWire.com) – Gilead Sciences K.K. and Eisai Co., Ltd. today announced that Gilead submitted an application to…